Accelerant Holdings
ARXNYSEUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $19.91 Prior regular-session close from the quote source.
- $19.87–$19.90 Regular-session low and high so far today.
- 571.0K Regular-session shares traded · Nov 11, 4:00 PM ET.
- Not yet confirmed The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
- $9.18–$19.91 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own ARX if its specialty-insurance marketplace keeps attracting both MGAs and risk capital without turning growth into balance-sheet insurance risk.
ARX price history
Loading recent earnings…
Investment thesis
What must happen next
Specialty MGAs continue to prefer Accelerant’s marketplace as a route to rated capacity and risk capital rather than building direct carrier or Lloyd’s relationships themselves.StrengtheningMateriality: High
GAAP annual revenue rose from $344.0 million in FY2023 to $602.6 million in FY2024 and $912.9 million in FY2025. If this holds, Accelerant can keep expanding premium flow; if it breaks, growth becomes dependent on price concessions or riskier programs.
Watch: Lloyd’s syndicates, traditional specialty carriers, or fronting competitors such as State National offer MGAs cheaper or more flexible capacity directly.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual revenue rose from $344.0 million in FY2023 to $602.6 million in FY2024 and $912.9 million in FY2025.
Open source ↗Risk-capital providers keep funding Accelerant programs because the platform gives them enough underwriting transparency and control to remain committed through the insurance cycle.HoldingMateriality: High
GAAP annual operating cash flow was positive in each supplied year: $290.0 million in FY2023, $785.7 million in FY2024, and $445.1 million in FY2025. The marketplace model depends on outside capital staying available; if capital withdraws or reprices sharply, Accelerant’s capacity and economics shrink before revenue does.
Watch: Reinsurers or alternative-capital partners pull back after catastrophe losses or adverse casualty development in Accelerant-supported programs.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating cash flow was positive in each supplied year: $290.0 million in FY2023, $785.7 million in FY2024, and.
Open source ↗Accelerant’s program selection and risk-sharing discipline must keep growth from being purchased with retained losses or adverse development.WeakeningMateriality: Medium
GAAP annual net income improved from a $64.1 million loss in FY2023 to $22.9 million of profit in FY2024, showing profitability was possible before the FY2025 loss. This is the difference between a valuable marketplace and an insurer taking mispriced tail risk; failure would consume equity and make revenue growth value-destructive.
Watch: Loss ratios in Accelerant-supported programs deteriorate because of casualty inflation, social inflation, or catastrophe concentration.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual net income improved from a $64.1 million loss in FY2023 to $22.9 million of profit in FY2024, showing.
Open source ↗Accelerant retains enough equity capital and liquidity to support regulated insurance capacity without being forced into dilutive or restrictive financing.StrengtheningMateriality: Medium
Stockholders’ equity increased from $304.3 million at FY2024 year-end to $697.7 million at FY2025 year-end. Adequate capital protects the platform’s ability to write and intermediate business; capital stress would hand bargaining power to reinsurers, regulators, and competitors.
Watch: Regulators or rating agencies require additional capital at Accelerant’s insurance entities after loss development or faster premium growth.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Stockholders’ equity increased from $304.3 million at FY2024 year-end to $697.7 million at FY2025 year-end.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Specialty MGAs continue to prefer Accelerant’s marketplace as a route to rated capacity and risk capital rather than building direct carrier or Lloyd’s relationships themselves. If this holds, Accelerant can keep expanding premium flow; if it breaks, growth becomes dependent on price concessions or riskier programs.
Risk-capital providers keep funding Accelerant programs because the platform gives them enough underwriting transparency and control to remain committed through the insurance cycle. The marketplace model depends on outside capital staying available; if capital withdraws or reprices sharply, Accelerant’s capacity and economics shrink before revenue does.
Accelerant’s program selection and risk-sharing discipline must keep growth from being purchased with retained losses or adverse development. This is the difference between a valuable marketplace and an insurer taking mispriced tail risk; failure would consume equity and make revenue growth value-destructive.
Accelerant retains enough equity capital and liquidity to support regulated insurance capacity without being forced into dilutive or restrictive financing. Adequate capital protects the platform’s ability to write and intermediate business; capital stress would hand bargaining power to reinsurers, regulators, and competitors.
All standing thesis claims
Original report summary
its specialty-insurance marketplace keeps attracting both MGAs and risk capital without turning growth into balance-sheet insurance risk.
Bull case and bear case
Bull case and bear case for Accelerant Holdings
Where the evidence on Accelerant Holdings disagrees: Mixed on the latest evidence (Oct 13, 2026). Of its 4 thesis points, 2 strengthening, 1 holding and 1 weakening.
Bull case: what the evidence supports
Specialty MGAs continue to prefer Accelerant’s marketplace as a route to rated capacity and risk capital rather than building direct carrier or Lloyd’s relationships themselves.
Risk-capital providers keep funding Accelerant programs because the platform gives them enough underwriting transparency and control to remain committed through the insurance cycle.
Accelerant retains enough equity capital and liquidity to support regulated insurance capacity without being forced into dilutive or restrictive financing.
Bear case: what the evidence questions
Accelerant’s program selection and risk-sharing discipline must keep growth from being purchased with retained losses or adverse development.
Thesis-Break Engine
What has broken in Accelerant Holdings’s thesis
Each break OptimistFi flagged on Accelerant Holdings, dated — with what has historically followed the same kind of break across the market, not a forecast for Accelerant Holdings.
- Analyst downgradecondition set before this filing
Across all companies, this kind of break has happened 12,641 times before. Those stocks trailed comparable companies by a median of 1% over the next six months, and 33% of them trailed it by 10 points or more.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedOther material event.
Accelerant Holdings filed an SEC 8-K on 2026-09-23: Other material event. It is a dated development that tests the current thesis.
- MixedEntered a material definitive agreement.
Accelerant Holdings filed an SEC 8-K on 2026-08-14: Entered a material definitive agreement. It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Accelerant Holdings filed an SEC 8-K on 2026-08-13: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Lloyd’s syndicates, traditional specialty carriers, or fronting competitors such as State National offer MGAs cheaper or more flexible capacity directly.
- Reinsurers or alternative-capital partners pull back after catastrophe losses or adverse casualty development in Accelerant-supported programs.
- Loss ratios in Accelerant-supported programs deteriorate because of casualty inflation, social inflation, or catastrophe concentration.
- Regulators or rating agencies require additional capital at Accelerant’s insurance entities after loss development or faster premium growth.
ARX news
Loading headlines…
Financial statements
ARX income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
ARX: quick answers
- Which well-known investors own ARX?
- 1 of the 37 well-known funds tracked here reported ARX shares in their latest 13F filing. By share of the fund's portfolio: Tiger Global Management (Chase Coleman), 0.0%. Fund portfolios
ARX in well-known investors’ portfolios
1 of 37 funds reported ARX shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.
| Fund | Of its portfolio | Value | Change | Quarter |
|---|---|---|---|---|
| Chase ColemanTiger Global Management | 0.00% | $879K | No change | Q2 2026 |
